The global Oral Mucositis Market size is expected to register 7.1% CAGR during the forecast period of 2019 to 2025, with a market value of USD 2,247 million in 2018. Oral mucositis is an acute inflammation or ulceration of the oral or oropharyngeal mucosal membranes. It can cause pain/discomfort, interfere with swallowing, eating, and speech, and may lead to infection. The global oral mucositis market is driven by factors such as rising incidences of cancer globally and increasing oral mucositis drug development. For instance, according to the National Center for Biotechnology Information, oral mucositis occurs in up to 40% of cancer patients that receive chemotherapy and approaches 100% in the treatment of head and neck cancers. Additionally, according to National Cancer Institute, an estimated 1,735,350 new cases of cancer were diagnosed in the US in 2018. Furthermore, according to the US Department of Health and Human Services, the prevalence of cancer in the US is 439.2 per 100,000 men and women. Moreover, according to WHO, there are 3.7 million cases of cancer in Europe every year. On the other hand, most of the drugs are not to be ingested, which restricts their usage for oral mucositis is projected to hamper the growth of the market during the assessment period. Moreover, major companies in the market are involved in strategic acquisitions, collaborations, and mergers, and receive new patents to sustain their position in the market. For instance, in February 2019, Innovation Pharmaceuticals receives new patent for compounds for use in treatment of oral mucositis. The patent covers methods for treating and/or preventing mucositis with one or more compounds, or pharmaceutically acceptable salts.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1531
Oral Mucositis Market Segmentation
The global oral mucositis market has been segmented based on cause, end user, and region.
The market, based on cause, has been bifurcated into oral mucositis caused by chemotherapy, oral mucositis caused by radiotherapy, and oral mucositis caused by hematopoietic stem cell transplantation
The global market, based on end user, has been segmented into hospitals, dental clinics, oncology hospitals, and research institutes. Based on cause, the oral mucositis caused by chemotherapy segment is expected to hold a major share in the market as chemotherapy is widely used as a treatment method for cancer. For example, according to the US Department of Health & Human Services, every year, about 650,000 cancer patients receive chemotherapy in an outpatient oncology clinic in the US. Based on end user, the hospitals segment is expected to hold a major share in the market due to its close association with cancer availability of all possible treatment options.
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The oral mucositis market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European oral mucositis market has been sub-divided into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The oral mucositis market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The oral mucositis market in the Middle East & Africa has been divided into the Middle East and Africa.
Global Oral Mucositis Market, by Cause
- Oral Mucositis Caused by Chemotherapy
- Oral Mucositis Caused by Radiotherapy
- Oral Mucositis Caused by Hematopoietic Stem Cell Transplantation
Global Oral Mucositis Market, by End User
- Hospitals
- Dental Clinics
- Oncology Hospitals
- Research Institutes
Key Players
The key players operating in the global oral mucositis market are Izun Pharmaceuticals Corporation, Shoreline Pharmaceuticals, Inc, AMAG Pharmaceutical Inc, Innovation Pharmaceuticals, The Himalaya Drug Company, Access pharmaceuticals, EKR therapeutics Inc, EUSA Pharma Inc, Swedish Orphan Biovitrum AB (publ), Soligenix, and Daewoong Co. Ltd.
Regional Market Summary:
The market in the Americas is expected to dominate the oral mucositis market due to the increasing incidences of head and neck cancers. For example, according to the American Society of Clinical Oncology (ASCO), head and neck cancer account for about 4% of all cancers in the US. In 2019, an estimated 65,410 people will develop head and neck cancer. High cases of cancer in the US and Canada is expected to drive the market growth. Furthermore, increasing expenses in research by healthcare bodies engaged in improving oral mucositis treatment are the factors contributing to its largest share is expected to fuel the growth of the market in this region. The market in Europe showed a considerable amount of growth. This can be attributed to the presence of a well-established healthcare system, an increase in cancer diseases, and the involvement of key companies. For instance, in April 2016, EUSA Pharma announces the acquisition of global rights to next-generation oncology supportive care product Arcoral Tab from Arcoral Pharma. The market in Asia-Pacific is projected to have a steady growth rate during the forecast period owing to the increasing prevalence of cancer and increasing government initiatives for healthcare reforms. The market in the Middle East & Africa is projected to account for the least share of the global market due to low per capita disposable income in the region.
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/oral-mucositis-market-1531
No comments:
Post a Comment